Harvard Bioscience (HBIO) Stock Price, News & Analysis

Company Overview

Harvard Bioscience, Inc. develops, manufactures and sells specialized tools and equipment used in life-science research. Its products support applications including drug discovery, preclinical research, cell and tissue studies, electrophysiology, organ and perfusion research, and regenerative medicine.

The company’s portfolio includes laboratory instruments, systems, consumables and related accessories for measuring, controlling and analyzing biological processes. Its offerings are used by academic and government research institutions, pharmaceutical and biotechnology companies, contract research organizations, and other laboratories.

Harvard Bioscience traces its history to Harvard Apparatus, which was established in 1901. The company serves customers internationally through direct sales and distribution channels, with operations and commercial activities supporting researchers in North America, Europe and other global markets.

Key Stats

• Today's Range: $7.91 to $8.04
• 50-Day Range: $5.92 to $8.20
• 52-Week Range: $3.75 to $9.40
• Volume: 4,538 shs
• Average Volume: 35,551 shs
• Market Capitalization: $36.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.75
• Consensus Rating: Hold

Harvard Bioscience Stock Analysis - MarketRank™

Harvard Bioscience scored higher than 18% of companies evaluated by MarketBeat, and ranked 824th out of 898 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

Harvard Bioscience has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Downside Risk

Harvard Bioscience has a consensus price target of $6.75, representing about 15.8% downside from its current price of $8.02.

Amount of Analyst Coverage

Harvard Bioscience has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Harvard Bioscience is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harvard Bioscience is -3.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Harvard Bioscience has a P/B Ratio of 2.61. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.28% of the float of Harvard Bioscience has been sold short.

Short Interest Ratio / Days to Cover

Harvard Bioscience has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Harvard Bioscience has recently decreased by 17.50%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harvard Bioscience does not currently pay a dividend.

Dividend Growth

Harvard Bioscience does not have a long track record of dividend growth.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

News Coverage This Week

MarketBeat has tracked 1 news article for Harvard Bioscience this week, compared to 2 articles on an average week.

Company Ownership

• Score: 1.3 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Harvard Bioscience insiders have not sold or bought any company stock.

Percentage Held by Insiders

17.03% of the stock of Harvard Bioscience is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

80.87% of the stock of Harvard Bioscience is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/11/2026
• Today: 9/22/2026
• Next Earnings (Estimated): 11/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NASDAQ:HBIO
• CIK: 1123494
• Web: www.harvardbioscience.com
• Phone: (508) 893-8999
• Fax: 508-429-5732
• Employees: 339
• Year Founded: 1901

Price Target and Rating

• Average Price Target for Harvard Bioscience: $6.75
• High Price Target: $7.50
• Low Price Target: $6.00
• Potential Upside/Downside: -16.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($2.31)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$56.70 million
• Net Margins: -11.86%
• Pretax Margin: -12.01%
• Return on Equity: -33.13%
• Return on Assets: -4.80%

Debt

• Debt-to-Equity Ratio: 4.94
• Current Ratio: 1.87
• Quick Ratio: 0.98

Sales & Book Value

• Annual Sales: $87.81 million
• Price / Sales: 0.42
• Cash Flow: $11.89 per share
• Price / Cash Flow: 0.68
• Book Value: $3.07 per share
• Price / Book: 2.63

Miscellaneous

• Outstanding Shares: 4,552,000
• Free Float: 3,777,000
• Market Cap: $36.80 million
• Optionable: No Data
• Beta: 1.53